Bayer to pay $160M as part of Onyx settlement

Bayer and Onyx Pharmaceuticals have resolved a longstanding dispute over the rights to a Nexavar follow-up drug. Bayer will pay $160 million plus royalties and give co-marketing rights to Onyx in return for control of the new drug's development and commercialization. Their partnership on Nexavar is mostly unchanged, the companies said. Release | News

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.